$CANFJun 26, 2026, 11:00 AMAI processed
Can‐Fite wins Japan patent allowance for Namodenoson anti‐obesity use
AI Summary
The Japan Patent Office allowed a divisional patent covering the use of A3 adenosine receptor agonists, including Can‐Fite's Namodenoson, to induce fat loss and treat obesity/metabolic disorders, adding Japan to the company’s existing IP protections. This strengthens Namodenoson's global exclusivity and partnering appeal, but the anti‐obesity case is supported by published/preclinical evidence and Namodenoson has not reported pivotal obesity clinical trial results (it is currently in Phase 3 for HCC and Phase 2b for MASH).
Positives
- Japan Patent Office allowed a patent covering Namodenoson/A3AR agonists for fat loss and obesity
- Expands global IP estate (adds Japan to existing patents in US, Canada, Australia, Israel)
- Allowed patent backed by a peer‑reviewed paper showing Namodenoson’s anti‑obesity activity
Negatives
- Anti‑obesity claim appears based on preclinical/published evidence, not pivotal clinical trial data
- Patent allowance is an IP milestone but does not guarantee final issuance or commercial/regulatory success
- Namodenoson is currently being developed for HCC (Phase 3) and MASH (Phase 2b), so obesity is a future indication